Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer:: Clinical outcome following tamoxifen-based adjuvant therapy
被引:20
作者:
Gago, FE
论文数: 0引用数: 0
h-index: 0
机构:CNR, Inst Expt Med & Biol Cuyo, Lab Oncol, IMBECU CONICET, RA-8555000 Mendoza, Argentina
Gago, FE
Fanelli, MA
论文数: 0引用数: 0
h-index: 0
机构:CNR, Inst Expt Med & Biol Cuyo, Lab Oncol, IMBECU CONICET, RA-8555000 Mendoza, Argentina
Fanelli, MA
Ciocca, DR
论文数: 0引用数: 0
h-index: 0
机构:CNR, Inst Expt Med & Biol Cuyo, Lab Oncol, IMBECU CONICET, RA-8555000 Mendoza, Argentina
Ciocca, DR
机构:
[1] CNR, Inst Expt Med & Biol Cuyo, Lab Oncol, IMBECU CONICET, RA-8555000 Mendoza, Argentina
[2] Argentine Fdn Canc Res, RA-8555000 Mendoza, Argentina
[3] Natl Univ Cuyo, Med Sch, Gynecol Dept, RA-5500 Mendoza, Argentina
estrogen receptors;
progesterone receptors;
Her-2/neu;
breast cancer;
tamoxifen;
D O I:
10.1016/j.jsbmb.2005.07.002
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
In breast cancer patients, the expression of steroid hormone receptors (HR:ER alpha/PR) appears inversely correlated with Her2/neu (not all reports agree on this negative correlation). Moreover, some but not all studies suggest that HR+/Her2/neu+ patients have a poor response to endocrine therapy, making this special group a matter of debate. In this prospective study we have analyzed the clinical outcome of our HR+/Her2/neu+ patients (n=51) selected from 516 consecutive stages I-II cases, with a follow-up 5-10 years (mean 7.3), treated with standard adjuvant therapy with tamoxifen (TAM) (TAM alone or TAM after chemotherapy). This group was compared with the HR+/Her2/neu- patients (n = 129) treated also with TAM. The tumor biopsies were studied by immunohistochemistry. We found that the association HR+/Her2/neu- was 2.5 times higher than the association HR+/Her2/neu+ (25% versus 9.9%, respectively). Our study also showed that the disease free survival (DFS) of the patients co-expressing HR and Her2/neu was significantly lower than those expressing HR but lacking of Her2/neu (p < 0.001). A similar result was obtained when the overall survival (OS) was evaluated (p = 0.001). All of these patients received hormone therapy with TAM, alone or after chemotherapy. When the analysis was performed in the patients treated with TAM alone, again the expression of Her-2/neu had a negative impact on both the DFS and the OS (P < 0.05). (c) 2005 Elsevier Ltd. All rights reserved.